African Health Sciences
Makerere University Medical School
Vol. 20, No. 3, 2020, pp. 1109-1117
Bioline Code: hs20084
Full paper language: English
Document type: Study
Document available free of charge
African Health Sciences, Vol. 20, No. 3, 2020, pp. 1109-1117
© Copyright 2020 - Adeoye-Isijola M et al.
Vancomycin intermediate resistant Staphylococcus aureus in the nasal cavity of asymptomatic individuals: a potential public health challenge|
Adeoye-Isijola, Morenike; Olajuyigbe, Olufunmiso; Adebola, Kehinde; Coopoosamy, Roger & Afolayan, Anthony
Background: The potential of transmitting multidrug resistant Staphylococcus aureus from asymptomatic individuals to healthy
individuals could constitute a great challenge to antimicrobial therapy.
Methods: The antibiograms of the S. aureus from asymptomatic individuals were determined by disk diffusion and agar
dilution assay techniques with different antibiotics and vancomycin.
Results: Of the 152 S. aureus isolated, (59)38.8% isolates were multi-drug resistant strains. Streptomycin was the most
effective and inhibited (135)88.82% of the isolates while ceftazidime inhibited (24)15.8% of the isolates. While (82)54.0%
of the isolates inhibited by cefuroxime had resistant colonies within their inhibition zones (Rc) and ofloxacin inhibited
(100)65.8% of the isolates without having resistant colonies within the inhibition zones, ceftazidime inhibited (7)4.6% of
the isolates with resistant colonies within the inhibition zones. Subjecting the isolates to vancomycin showed that (27)17.8%
were resistant to 2 μg/ml, (43)28.3% were resistant to 4 μg/ml and (27)17.8% of the isolates were simultaneously resistant
to both concentrations of vancomycin. Although (100)65.8% of the isolates had MARindex ≥0.2, (52)34.2% of the isolates
had MARindex ≤ 0.2 and (65)428% of the isolates were considered multidrug resistant strains.
Conclusion: The isolation of multi-drug and vancomycin intermediate resistant strains of S. aureus in high percentage, in
this study, presents a great threat to clinicians and general populace. The vancomycin intermediate resistant S. aureus (VISA)
in asymptomatic individuals could be a critical concern to the therapeutic dilemma to be added to the presence of multi-drug
resistance. A more sustainable therapy must be in place to prevent its dissemination or the outbreak of its infection.
Antibacterial activity; multidrug resistance; VRSA; VISA; vancomycin